Two naturally occurring insulin receptor tyrosine kinase domain mutants provide evidence that phosphoinositide 3-kinase activation alone is not sufficient for the mediation of insulin's metabolic and mitogenic effects by Krook, A et al.
Two Naturally Occurring Insulin Receptor Tyrosine Kinase Domain
Mutants Provide Evidence That Phosphoinositide 3-Kinase
Activation Alone Is Not Sufficient for the Mediation of Insulin’s
Metabolic and Mitogenic Effects*
(Received for publication, April 7, 1997, and in revised form, September 8, 1997)
Anna Krook‡§¶i, Jonathan P. Whitehead‡§i, Stephen P. Dobson**, Matthew R. Griffiths**,
Margrite Ouwens‡‡, Claire Baker‡§, Amanda C. Hayward§, Sankhya K. Sen**,
J. Antoine Maassen‡‡, Kenneth Siddle§, Jeremy M. Tavare´**, and Stephen O’Rahilly‡§ §§
From the Departments of ‡Medicine and §Clinical Biochemistry, Cambridge University, Addenbrookes Hospital, Hills
Road, CB2 2QR, Cambridge, United Kingdom, **Department of Biochemistry, University of Bristol, Bristol, United
Kingdom, and ‡‡Department of Medical Biochemistry, Sylvius Laboratories, University of Leiden, The Netherlands
We have recently reported (1) that two naturally oc-
curring mutants of the insulin receptor tyrosine kinase
domain, Arg-1174 3 Gln and Pro-1178 3 Leu (Gln-1174
and Leu1178, respectively), both found in patients with
inherited severe insulin resistance, markedly impaired
receptor tyrosine autophosphorylation, with both mu-
tant receptors being unable to mediate the stimulation
of glycogen synthesis or mitogenesis by insulin when
expressed in Chinese hamster ovary cells. However,
these mutations did not fully prevent IRS-1 phosphoryl-
ation in response to insulin in these cells, suggesting
that IRS-1 alone may not be sufficient to mediate insu-
lin’s metabolic and mitogenic effects. In the present
study, we have demonstrated that these mutations also
impair the ability of the insulin receptor to activate the
transcription factor Elk-1 and promote GLUT4 translo-
cation to the plasma membrane. Although at low con-
centrations of insulin, the mutant receptors were im-
paired in their ability to stimulate the tyrosine
phosphorylation of IRS-1, at higher insulin concentra-
tions we confirmed that the cells expressing the mutant
receptors showed significantly increased tyrosine phos-
phorylation of IRS-1 compared with parental nontrans-
fected cells. In addition, at comparable insulin concen-
trations, the association of the p85a subunit of
phosphoinositide 3-kinase (PI3-kinase) with IRS-1 and
the enzymatic activity of IRS-1-associated PI3-kinase
were significantly enhanced in cells expressing the mu-
tant receptors. In contrast, no significant stimulation of
the tyrosine phosphorylation of Shc, GTP loading of
Ras, or mitogen-activated protein kinase phosphoryla-
tion was seen in cell lines expressing these mutant re-
ceptors. Thus, no activation of any measurable mitogenic
or metabolic response was detectable, despite significant
insulin-induced phosphorylation of IRS-1 and its associa-
tion with PI3-kinase in cells stably expressing the mutant
insulin receptors. These findings suggest that PI3-kinase
activation alone may be insufficient to mediate a wide
range of the metabolic and mitogenic effects of insulin.
Additionally, the data provide support for the notion
that insulin activation of Ras is more closely linked with
Shc, and not IRS-1, phosphorylation.
Mutations of the insulin receptor gene have been identified
in patients with a wide variety of genetic syndromes of severe
insulin resistance (for reviews see Refs. 2 and 3). Studies of the
functional properties of these mutant insulin receptors have
contributed to the understanding of molecular mechanisms
involved in insulin signaling. The insulin receptor is a het-
erotetrameric receptor tyrosine kinase composed of two extra-
cellular a subunits and two b subunits. Insulin binds to the a
subunit of the receptor, an event which activates the tyrosine
kinase function of the cytoplasmic domain of the b subunit.
This results in autophosphorylation of the b subunit of the
receptor itself as well as the phosphorylation of a number of
cytoplasmic target proteins that include IRS-1, IRS-2, and Shc
(for review see Ref. 4). These tyrosine-phosphorylated mole-
cules are involved in the coupling of the insulin receptor to
downstream metabolic and mitogenic events. Thus, the phos-
phorylation of IRS-1 generates a number of recognition sites for
interaction with SH2 domain-containing molecules, including
the lipid kinase PI3-kinase, the phosphatase SHP-2, and the
adaptor proteins Grb2 and Nck. The phosphorylation of Shc
also facilitates its interaction with the SH2 domain of Grb2.
Grb2, in tight association with the guanine nucleotide ex-
change factor Sos, is closely involved with insulin stimulation
of Ras activation (5).
A large body of evidence exists to support the hypothesis that
the activation of the tyrosine kinase activity of the insulin
receptor is an essential first step for most, if not all, of the
biological effects of insulin (6, 7). Thus, mutant insulin recep-
tors where the ATP binding site has been altered by site-
directed mutagenesis or naturally occurring insulin receptor
mutations abolishing receptor tyrosine kinase activity fail to
mediate any biological effects of insulin when expressed in
transfected cells (8, 9). The importance of IRS-1 tyrosine phos-
phorylation in the mediation of insulin’s downstream effects
has also been highlighted by several studies. Insulin receptors
in which tyrosine 972 was replaced by phenylalanine were
capable of insulin-stimulated autophosphorylation but were
markedly impaired in their interaction and phosphorylation of
IRS-1 (10–12). Cells expressing this mutant insulin receptor
showed severely impaired insulin stimulation of glycogen syn-
thesis, thymidine incorporation, and amino acid uptake, sug-
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gesting that receptor autophosphorylation per se might be less
relevant to insulin signaling than the ability to phosphorylate
downstream substrates (10). Further support for the impor-
tance of IRS-1 phosphorylation in mediating the insulin signal
comes from studies of a truncated insulin receptor lacking the
82 C-terminal amino acids (D82) (13). This receptor displayed
severely impaired autophosphorylation, whereas insulin-stim-
ulated tyrosine phosphorylation of IRS-1 was unaffected. De-
spite this receptor-impaired ligand-induced autophosphoryla-
tion, Chinese hamster ovary (CHO)1 cells expressing this
mutant insulin receptor were able to mediate insulin-stimu-
lated thymidine incorporation into DNA as well as insulin-
stimulated glucose uptake. Furthermore, in 32D cells, which
normally do not contain either the insulin receptor or IRS-1 or
-2, insulin-responsive mitogenesis cannot be conferred by
transfecting either the insulin receptor or IRS-1 but only by
coexpressing both molecules (14). Although the targeted dele-
tion of IRS-1 in mice is not lethal, 2/2 mice show significant
impairment in insulin-stimulated glucose metabolism and re-
duced size, despite the normal phosphorylation of IRS-2 and
Shc (15, 16). These data provide further support for the central
importance of IRS-1 phosphorylation in the mediation of insu-
lin action.
We have recently described two insulin receptor mutations,
Gln-1174 and Leu-1178, found in patients with inherited forms
of severe insulin resistance (1). When stably expressed in CHO
cells, these receptors showed severely impaired autophospho-
rylation and in vitro tyrosine kinase activity toward artificial
substrates but retained the ability to phosphorylate IRS-1. In
contrast to findings with the D82 receptor (see above), these
receptors were also severely impaired in their ability to medi-
ate both the metabolic (as measured by glycogen synthesis) and
mitogenic (as measured by thymidine incorporation) effects of
insulin.
We now present further characterization of the signaling
properties of these insulin receptors. These new studies provide
evidence that insulin-stimulated PI3-kinase activity, although
undoubtedly important for insulin action, may not in itself be
sufficient to mediate the full metabolic and mitogenic actions of
insulin. They also provide supportive evidence that insulin
activation of Ras may be more closely related to Shc rather
than IRS-1 phosphorylation.
EXPERIMENTAL PROCEDURES
Patient Characteristics—Both mutations were identified in heterozy-
gous form in adolescent females suffering from the Type A syndrome of
insulin resistance. Insulin resistance was inherited in a dominant fash-
ion in both families and co-segregated with the mutation. The identifi-
cation and initial characterization of both mutations has been described
previously (1, 17, 18).
Cell Lines—Construction of CHO cell lines expressing Gln-1174 or
Leu-1178 insulin receptors has been described previously (1). CHO cells
were grown in F-12 medium supplemented with 10% fetal bovine se-
rum, penicillin (100 units/ml), and streptomycin (100 mg/ml) at 37 °C
under an atmosphere of 95% air and 5% CO2.
Antibodies—Anti-IRS-1 and anti-Shc antibodies (polyclonal) were
raised against GST fusion proteins containing IRS-1 amino acids 511–
860 and Shc amino acids 366–473, respectively. A monoclonal anti-
p85a antibody (U2) was a gift from Dr. Mike Waterfield (University
College London, UK). Phospho-specific p44/42 MAP kinase antibody
was purchased from New England Biolabs, and anti-Ras antibody Y13-
259 was purchased from Oncogene Science. Anti-phosphotyrosine anti-
body was purchased from Upstate Biotechnology, Inc. (clone 4G10).
Cell Transfections and Reporter Gene Assays—CHO.K1 cells at
;80% confluence in 12-mm dishes were transfected for 2 h with four
plasmids: (i) pCMV.hIR, the wild-type IR or mutants thereof, under the
control of the nonregulated CMV promoter, (ii) pGL3.G5E4D[D]38, the
firefly luciferase reporter plasmid, which possesses five GAL4 binding
sites upstream of the firefly luciferase gene in the plasmid pGL3 (Pro-
mega Corp.), (iii) pRL.CMV, Renilla luciferase under the control of the
CMV promoter, and (iv) pSG424.Elk1 (83–428), fusion of the GAL4
DNA binding domain and Elk-1 activation domain. Transfections were
performed using Tfx-50 (Promega Corp.) transfection reagent (2.2 mg of
Tfx-50/mg of DNA in 5% serum-free Ham’s F-12). The dishes were
further incubated in Ham’s F-12 containing 5% fetal calf serum for 4 h,
then washed with phosphate-buffered saline and serum-starved for 2 h.
The cells were stimulated with 100 nM insulin for 16 h. The cells were
then extracted using Stop and GloR lysis buffer and assayed sequen-
tially for the firefly and Renilla luciferases according to the manufac-
turer’s instructions (Promega Corp.). In brief, 10 ml of crude cell lysate
was incubated with 50 ml of luciferin reagent (LARII). After 15 s at room
temperature, the luminescence was recorded for 30 s in a Berthold
Lumat LB9501 luminometer. 50 ml of Stop and GloR reagent was added,
and the specific luminescence from the Renilla luciferase was recorded
for an additional 30 s.
Cell Microinjection and Analysis of GLUT4 Trafficking—CHO.K1
cells on 22-mm-diameter glass coverslips were co-microinjected as de-
scribed previously (19) with two plasmids; pCMV.hIR (or mutants
thereof) at 50 mg/ml and pcDNAneoI possessing a chimera between
green fluorescent protein (GFP) fused to the N terminus of GLUT4 at
200 mg/ml. Cells were incubated in growth medium for 16–24 h before
serum starvation for 2 h. The cells were subjected to fluorescence
analysis in Hepes-buffered Krebs (10 mM Hepes, pH 7.4, 2 mM NaHCO3,
140 mM NaCl, 3.6 mM KCl, 0.6 mM Na2HPO4, 0.5 mM MgSO4, 1 mM
CaCl2, and 5.5 mM glucose) using a Zeiss Axiovert 100TV microscope
with a 40 3 oil immersion objective. GFP excitation/emission was
achieved with a High Q fluorescein isothiocyanate filter set (Chroma
Technology Corp., Brattleboro, VT). Treatment with insulin (100 nM)
was for 60 min.
Immunoprecipitation and Western Blotting—Immunoprecipitation
and Western blotting was carried out essentially as described previ-
ously (1), except blots were probed with 125I-labeled secondary antibod-
ies and proteins were visualized by autoradiography and quantified by
phosphoimaging using a Fujix BAS 2000 phosphoimager.
Phosphoinositide 3-Kinase Assay—PI3-kinase activity was assayed
using a protocol adapted from Jackson et al. (20). Cells were grown until
confluency in 3.5-cm (6 well) plates, incubated overnight in serum-free
Ham’s F-12 media, and then treated with insulin (100 nM) for 5 min.
Incubations were terminated by aspirating the medium and rinsing
briefly with ice-cold phosphate-buffered saline before the addition of
500 ml of ice-cold freshly prepared PI3-kinase lysis buffer A (20 mM Tris,
pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 500 mM NaVO3, 1%
Nonidet P-40, 10% (w/v) glycerol, 10 mg/ml leupeptin, and 200 mM
phenylmethylsulfonyl fluoride). The lysates were cleared by centrifuga-
tion and incubated with anti-IRS-1 antibody (1 in 100 dilution) and 50
ml of protein A-Sepharose (50 mg/ml pre-equilibrated in lysis buffer A)
by tumbling end over end at 4 °C for 2 h. The immunoprecipitates were
then washed 3 times with lysis buffer A, 2 times in buffer B (500 mM
LiCl, 100 mM Tris-HCl, pH 8.0, at 4 °C), once in buffer C (150 mM NaCl,
10 mM Tris-HCl, 1 mM EDTA, pH 7.6, at 4 °C), and once in buffer D (20
mM Hepes, 1 mM dithiothreitol, 5 mM MgCl2, pH 7.6, at 4 °C). The
beads were then resuspended in 40 ml of buffer E (10 mM b-glycero-
phosphate, 5 mM Na4P2O7, 30 mM NaCl, 1 mM dithiothreitol, pH 7.2,
at 4 °C). 20 ml of phosphatidylinositol/cholate solution (3 mg/ml in 1%
(w/v) sodium cholate) was added to each tube, and the reaction was
started by the addition of 5 mCi of [g-32P]ATP in 40 ml of reaction mix
(3 mM Na2ATP, 7.5 mM MgCl2) and incubated at 37 °C for 15 min.
Reactions were terminated by the addition of 450 ml of CHCl3:CH3OH
(1:2 v/v). The product was then extracted by the addition of 150 ml of
CHCl3 and 150 ml of 0.1 M HCl and then again by the addition of 300
ml of CHCl3 and 300 ml of 0.1 M HCl. Extracted lipid was dried down
under vacuum before redissolving in 25 ml of CHCl3, CH3OH, 0.1 M HCl
(200:100:1). Reaction products were separated by thin layer chromatog-
raphy (run in a pre-equilibrated tank containing methanol:chloroform:
ammonia:water, 300:210:45:75) and quantified using a Fujix Bas 2000
phosphoimager.
GTP Loading of Ras—Analysis of the GDP/GTP ratio on Ras was
determined as described previously (21). Briefly, cells were grown until
confluency in 4-cm dishes, serum-starved overnight, then labeled with
[32P]orthophosphate before being stimulated with insulin (100 nM, 5
min). Cells were then lysed in a buffer containing 1% Triton X-114.
Lysates were cleared by centrifugation, and the Triton X-114-soluble
material was collected by a short temperature shift. The detergent
1 The abbreviations used are: CHO, Chinese hamster ovary; PI3-
kinase, phosphoinositide 3-kinase; CMV, cytomegalovirus; GFP, green
fluorescent protein; MAP, mitogen-activated protein; IR, insulin
receptor.
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phase was then used to immunoprecipitate Ras. Guanine nucleotides
were eluted from the immune complex and resolved by thin layer
chromatography. The plates were visualized by autoradiography and
quantitated using a Fujix Bas 2000 phosphoimager.
RESULTS
We have previously reported that the mutant insulin recep-
tors Gln-1174 or Leu-1178 are unable to autophosphorylate
and that CHO cells stably expressing these receptors are se-
verely defective in insulin-stimulated glycogen synthesis and
thymidine incorporation (1). Unexpectedly, significant insulin-
stimulated IRS-1 phosphorylation was seen in both cell lines
expressing the mutant insulin receptors using anti-phosphoty-
rosine blotting of total cell lysates and anti-IRS-1 immunopre-
cipitates (1). These observations suggested to us that IRS-1
phosphorylation per se may be insufficient to mediate down-
stream insulin signaling events. This possibility was further
explored by more detailed characterization of the signaling
properties of the CHO cell lines stably expressing similar num-
bers of wild-type, Gln-1174, or Leu-1178 insulin receptors
termed wild-type, Gln-1174, or Leu-1178 cell lines,
respectively.
To more precisely define the dose response characteristics of
IRS-1 tyrosine phosphorylation, all cell lines were treated with
various concentrations of insulin for 2 min, and IRS-1 immu-
noprecipitates were analyzed by anti-phosphotyrosine blotting
(Fig. 1). At 100 nM insulin, the Gln-1174 and Leu-1178 cell lines
show significant enhancement of insulin-stimulated tyrosine
phosphorylation of IRS-1 compared with parental nontrans-
fected CHO cells, although this was somewhat reduced com-
pared with the wild-type cell line. The levels of IRS-1 phospho-
rylation seen in the Gln-1174 and Leu-1178 cell lines
stimulated with 100 nM insulin and the wild-type cell line
stimulated with 1 nM insulin were comparable. Thus, while we
confirmed the ability of the mutant receptors to promote insu-
lin-stimulated tyrosine phosphorylation of IRS-1, these mutant
receptors did so less well than wild-type receptors.
In parallel immunoblotting studies, insulin ability to pro-
mote the association of the p85a subunit of PI3-kinase with
IRS-1 was examined. Consistent with the studies of IRS-1
phosphorylation, association of p85a with IRS-1 in response to
insulin was significantly enhanced in the Gln-1174 and Leu-
1178 cell lines compared with parental CHO cells (Fig. 1).
Again, similar levels of IRS-1-associated p85a were seen when
the Gln-1174 and Leu-1178 cell lines were treated with 100 nM
insulin versus 1 nM insulin treatment of the wild-type cell line.
To examine whether the insulin-stimulated association of
p85a seen in cells expressing the mutant receptors could result
in the functional activation of PI3-kinase, IRS-1-associated
PI3-kinase activity was measured in all cell lines. Parental
CHO cells and Gln-1174 and Leu-1178 cells were incubated
with 100 nM insulin for 5 min, whereas wild-type cells were
incubated with either 1 or 100 nM insulin for 5 min. PI3-kinase
activity in IRS-1 immunoprecipitates from wild-type cells
(stimulated with either 1 or 100 nM insulin) or Gln-1174 and
Leu-1178 cells showed a stimulation that was significantly
greater (p , 0.03) than that seen in parental CHO cells (Fig. 2).
Also, PI3-kinase activity was comparable in wild-type cells
stimulated with 1 nM insulin and Gln-1174 and Leu-1178 cells
stimulated with 100 nM insulin.
Thus the Gln-1174 and Leu-1178 mutant receptors, despite
showing undetectable autophosphorylation, are capable of
phosphorylating IRS-1 such that it can interact with and acti-
vate PI3-kinase. Of note, using the identical cell lines, we have
previously reported that exposure of the wild-type cell line to 1
nM insulin results in a marked enhancement of glycogen syn-
thesis (;60% maximal), whereas no significant enhancement
of glycogen synthesis was seen in the Gln-1174 and Leu-1178
cell lines when studied at concentrations of 100 nM insulin or
higher (1). There is therefore a clear discordance between the
abilities of these mutant receptors to activate IRS-1-associated
PI3-kinase activity and to stimulate glycogen synthesis.
To provide additional confirmation that metabolic signaling
through the mutant receptors was markedly impaired, we mon-
itored the translocation of GLUT4 to the plasma membrane in
FIG. 1. CHO cells expressing Gln-1174 and Leu-1178 mutant
insulin receptors mediate insulin-stimulated tyrosine phospho-
rylation of IRS-1 as well as association of p85a with IRS-1. a, cells
were grown to confluence, serum starved, and left untreated or treated
with insulin (1, 10, or 100 nM) for 2 min. Cells were harvested, and
lysates were immunoprecipitated with anti-IRS-1 antibody as described
under “Experimental Procedures.” After electrophoresis on a 7.5% poly-
acrylamide gel, proteins were transferred to polyvinylidene difluoride
membrane and probed with anti-phosphotyrosine (anti PY) (region of
blot containing IRS-1) or anti-p85a antibodies, as indicated. b, graph
showing quantitative analysis of IRS-1 phosphorylation shown in a. wt,
wild type.
FIG. 2. CHO cells expressing Gln-1174 and Leu-1178 mutant
insulin receptors mediate insulin stimulation of PI3-kinase ac-
tivity. Cells were grown to confluence, serum starved, and left un-
treated (open bars) or treated with 100 nM insulin (shaded bars) or 1 nM
insulin (hatched bar) for 5 min. Cells were harvested, lysates were
immunoprecipitated with anti-IRS-1 antibody, and immune complexes
were assayed for their ability to phosphorylate phosphatidylinositol as
described under “Experimental Procedures.” Reaction products were
resolved by thin layer chromatography, and results were quantitated on
a phosphoimager. Results shown are standardized to the maximum
response of insulin (in cells expressing wild-type (wt) insulin receptors).
The data are the mean 1 S.E. from three independent experiments,
each performed in duplicate. The inset is taken from a representative
experiment showing stimulation at 100 nM for each cell line.
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CHO cells by taking advantage of the recently described fluo-
rescent chimera between GLUT4 and GFP (19). In CHO.T cells
that stably overexpress wild-type insulin receptors, we have
previously demonstrated that this chimera translocates to the
cell surface in response to insulin in approximately 60% of cells
(19). We confirmed this observation in CHO.K1 cells using
co-microinjection to transiently overexpress wild-type insulin
receptors and GFP-GLUT4 (Fig. 3). Cells injected with GFP-
GLUT4 and control vector mediated no significant increase in
GFP-GLUT4 translocation in response to insulin. In addition,
neither the Gln-1174 or Leu-1178 mutant insulin receptors
mediated insulin-stimulated GFP-GLUT4 translocation. These
results provide additional confirmation that metabolic signal-
ing is severely impaired in the Gln-1174- and Leu-1178-ex-
pressing cells. However, as we did not specifically compare
wild-type and mutant receptors at insulin concentrations pro-
ducing comparable degrees of PI3-kinase activation, we cannot
use these data to draw any direct conclusions regarding the
role of PI3-kinase in the mediation of this particular process.
With respect to the mitogenic effects of insulin, we have
previously demonstrated that the Gln-1174 and Leu-1178 mu-
tant receptors are unable to mediate insulin stimulation of
thymidine incorporation into DNA or to activate the enzymatic
activity of MAP kinase (1). To examine events relating to in-
sulin’s mitogenic actions in more detail under conditions where
cells expressing mutant and wild-type receptors demonstrated
comparable levels of IRS-1 phosphorylation and PI3-kinase
activation, the characteristics of MAP kinase phosphorylation
were examined in all cell lines. Whereas cells overexpressing
wild-type insulin receptors showed a 3-fold stimulation of MAP
kinase tyrosine phosphorylation in response to 1 nM insulin
and an approximate 5-fold stimulation following 100 nM insulin
treatment, no such phosphorylation was seen in the Gln-1174
and Leu-1178 cell lines (Fig. 4). To provide independent con-
firmation of the inability of these mutant receptors to activate
downstream effects related to mitogenesis, we examined the
ability of these mutant receptors to activate the ternary com-
plex factor Elk-1. This factor forms a complex with serum
response factor at the serum response element within the c-fos
promoter and is responsible for the observed insulin effect on
c-fos induction in CHO cells.2 The activation of this transcrip-
tion factor is closely associated with the proliferative response
of cells to growth stimuli (23). A GAL4-Elk-1 fusion protein was
expressed in CHO.K1 cells by transient transfection. The ac-
tivity of this chimeric transcription factor was monitored with
a co-transfected luciferase reporter plasmid, where the lucifer-
ase gene is placed under the control of a promoter possessing
five GAL4 binding sites. A third plasmid, pRL.CMV, possessing
the Renilla retinformis luciferase was included in these trans-
fections to monitor cell transfection efficiency. Finally, a fourth
plasmid was included to overexpress wild-type, Gln-1174, or
Leu-1178 mutant insulin receptors. As shown in Fig. 5, paren-
tal CHO.K1 cells exhibited little or no stimulation of Elk-1 in
response to insulin, as determined by luciferase activity. When
the wild-type insulin receptor was overexpressed, insulin in-
duced an approximate 2-fold increase in luciferase activity
after incubation with 1 nM insulin and an approximate 5-fold
increase in luciferase activity after incubation with 100 nM
insulin. In contrast, neither mutant insulin receptor was capa-
ble of activating Elk-1 (Fig. 5).
Thus, at concentrations of insulin that produced comparable
levels of IRS-1 phosphorylation and PI3-kinase activation in
wild-type- versus mutant receptor-expressing cell lines, CHO
cells expressing the mutant receptors were markedly impaired
in their ability either to phosphorylate MAP kinase or to acti-
vate transcription through Elk-1.
To explore whether the capacity of these mutant receptors to
phosphorylate IRS-1 was preserved for other substrates of the
receptor kinase, the ability of these receptors to phosphorylate
Shc was investigated. Cell lines were incubated with 100 nM
insulin for 5 min, and Shc immunoprecipitates were analyzed
by anti-phosphotyrosine blotting (Fig. 6). Only wild-type cells
exhibited insulin-stimulated tyrosine phosphorylation of Shc.
Stimulation of wild-type cells with 1 nM insulin invoked an
approximate 2-fold increase in Shc phosphorylation and Shc-
2 M. R. Griffiths, E. J. Black, M. Dickens, P. E. Shaw, D. A. F.
Gillespie, and J. M. Tavare´, submitted for publication.
FIG. 3. CHO cells expressing Gln-1174 and Leu-1178 mutant
insulin receptors fail to mediate insulin-stimulated GLUT4
translocation to the plasma membrane. CHO.K1 cells were micro-
injected with pGFP.GLUT4 and either empty vector (vector) or vector
encoding wild-type insulin receptor cDNA (wt), Gln-1174, or Leu-1178
mutant insulin receptors, as indicated. After 16 h, the cells were serum-
starved for 2 h. The fraction of cells exhibiting plasma membrane-
associated GFP-GLUT4 was scored by fluorescence microscopy (open
bars). The cells were then treated with insulin (100 nM) for 1 h, and the
fraction of cells exhibiting plasma membrane-associated GFP-GLUT4
re-scored (shaded bars). The data are mean 1 S.E. from three inde-
pendent experiments. The total number of cells imaged for each condi-
tion is indicated below the bars.
FIG. 4. CHO cells expressing Gln-1174 and Leu-1178 mutant
insulin receptors fail to mediate insulin stimulation of MAP
kinase phosphorylation. Cells were grown to confluence, serum
starved, and left untreated (open bars) or treated with 100 nM insulin
(shaded bars) or 1 nM insulin (hatched bar) for 5 min. Cells were
harvested, and protein lysates electrophoresed on 7.5% polyacrylamide
gels followed by transfer to polyvinylidene difluoride membrane. Mem-
branes were probed using phospho-specific p44/42 MAP kinase anti-
body as described under “Experimental Procedures.” Results shown are
standardized to the maximum response of insulin (in cells expressing
wild-type (wt) insulin receptors). The data are the mean 1 S.E. from
three independent experiments, each performed in duplicate. The inset
is taken from a representative experiment showing stimulation at 100
nM for each cell line.
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associated Grb2 and an approximate 6-fold increase in Shc
phosphorylation and Grb2 association with Shc after 100 nM
insulin treatment (data not shown).
At 100 nM insulin, these mutant insulin receptors show a
clear discordance in their ability to phosphorylate two down-
stream targets of the insulin receptor, i.e. IRS-1 and Shc. As
the relative roles of IRS-1 and Shc in the mediation of insulin
activation of Ras has been an area of some debate (21, 24, 25),
we utilized the divergent signaling to IRS-1 versus Shc seen in
the Gln-1174 and Leu-1178 cell lines to explore this issue
further. Cells were labeled with [32P]orthophosphate and stim-
ulated with 100 nM insulin, and GTP/GDP association with Ras
was determined in Ras immunoprecipitates (Fig. 7). Wild-type
cells show a significant insulin-stimulated increase in the GTP
loading of Ras. In contrast, no such increase was seen in Gln-
1174 and Leu-1178 cells. As, at this concentration of insulin,
the mutant receptors phosphorylate IRS-1 but not Shc, these
findings provide support for the notion that insulin signaling to
GTP loading of Ras is more closely associated with Shc, rather
than IRS-1, phosphorylation.
DISCUSSION
Two mutant insulin receptors, Gln-1174 and Leu-1178, iden-
tified in patients suffering from the inherited Type A syndrome
of severe insulin resistance, showed unusual signaling proper-
ties when expressed and studied in CHO cells. We have previ-
ously reported that despite having severely impaired autophos-
phorylation and in vitro tyrosine kinase activity (1), these
receptors are capable of mediating significant insulin-stimu-
lated tyrosine phosphorylation of IRS-1. We have extended our
initial observations by characterizing the insulin dose-respon-
siveness of IRS-1 phosphorylation in cells stably expressing
these mutant receptors. Although at 100 nM insulin, the mu-
tant insulin receptors promoted tyrosine phosphorylation of
IRS-1 to an extent that is between 60–80% that seen by wild-
type receptors, at lower concentrations of insulin the response
is more markedly impaired. Thus, even at the very elevated
plasma insulin concentrations seen in the patients harboring
these mutations, the mutant receptors might be expected to be
impaired in their ability to mediate insulin-stimulated IRS-1
phosphorylation in vivo. This impairment is likely to be a
significant contributor to the insulin resistance seen in the
patients.
However, the finding of a dissociation between receptor au-
tophosphorylation and IRS-1 phosphorylation in stably trans-
fected CHO cells expressing the mutant receptors provided the
opportunity to dissect insulin post-receptor signaling mecha-
nisms. We have demonstrated significant insulin-stimulated
tyrosine phosphorylation of IRS-1 in response to 100 nM insulin
in cells expressing the mutant receptors, with the degree of
IRS-1 phosphorylation being equivalent to that seen in cells
expressing wild-type receptors after stimulation with 1–10 nM
insulin. Previously (1), we have shown that stimulation of cells
expressing wild-type receptors with 1–10 nM insulin is suffi-
cient to stimulate 60–95% of maximal glycogen synthesis and
thymidine incorporation, indicating that such levels of IRS-1
phosphorylation are capable of mediating downstream effects.
However, despite comparable IRS-1 phosphorylation after
treatment of the Gln-1174 and Leu-1178 cell lines with 100 nM
insulin, glycogen synthesis and thymidine incorporation were
not significantly stimulated. One possibility for this was that
the phosphorylation of IRS-1 by the mutant receptors may be
qualitatively abnormal. For example, as anti-phosphotyrosine
FIG. 5. CHO cells expressing Gln-1174 and Leu-1178 mutant
insulin receptors fail to mediate insulin stimulation of a GAL4-
Elk1 transcription factor. CHO.K1 cells were transiently transfected
with pRL.CMV, pSG424.Elk1(83–428), and pGL3.G5E4D[D]38. Also
included was a fourth plasmid, either empty vector (vector), vector
encoding wild-type insulin receptor cDNA (wt), or vector encoding ei-
ther Gln-1174 or Leu-1178 mutant insulin receptors, as indicated.
Transfected cells were then treated in the absence (open bars) or pres-
ence of 100 nM insulin (shaded bars) or 1 nM insulin (hatched bar). After
16 h, the cells were harvested, and lysates were assayed for firefly and
Renilla luciferases as described under “Experimental Procedures.” Re-
sults shown are the ratio of the firefly luciferase/Renilla luciferase
activities (i.e. corrected for transfection efficiency) and are standardized
to the maximal response of insulin (in cells expressing wild-type insulin
receptors). The data are mean 1 S.E. from two independent experi-
ments, each performed in duplicate.
FIG. 6. CHO cells expressing Gln-1174 or Leu-1178 mutant in-
sulin receptors are unable to mediate insulin-stimulated tyro-
sine phosphorylation of Shc. Cells were grown to confluence, serum
starved, and untreated or treated with insulin (100 nM) for 5 min as
indicated. Cells were harvested, and lysates were immunoprecipitated
with anti-Shc antibody as described under “Experimental Procedures.”
After nonreducing electrophoresis on a 7.5% polyacrylamide gel, pro-
teins were transferred to polyvinylidene difluoride membrane and
probed with anti-phosphotyrosine antibodies. wt, wild type.
FIG. 7. CHO cells expressing Gln-1174 or Leu-1178 mutant in-
sulin receptors are unable to mediate insulin-stimulated GTP
loading of Ras. Cells were grown to confluence, serum-starved, la-
beled with [32P]orthophosphate, and untreated or treated with insulin
(100 nM) for 5 min. Cells were harvested, lysates were immunoprecipi-
tated with anti-Ras antibody, and immune complexes were assayed for
GDP and GTP content as described under “Experimental Procedures.”
Products were resolved by thin layer chromatography, and results were
quantitated on a phosphoimager. Data shown are standardized against
the response seen in parental CHO cells and represent the mean 1 S.E.
from three independent experiments. wt, wild type.
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blotting detects the sum of all phosphotyrosines, it is conceiv-
able that the mutant receptors do not phosphorylate IRS-1 on
the same residues as wild-type receptors. As PI3-kinase is the
SH2 domain-containing protein interacting with IRS-1 that
has been most closely linked with metabolically relevant insu-
lin signaling, we have concentrated on the examination of this
interaction. Insulin (100 nM) did indeed stimulate the associa-
tion of the p85a subunit of PI3-kinase with IRS-1 in the cells
expressing the mutant receptors, and the IRS-1-associated ho-
loenzyme had functional activity, findings that support the
notion that functionally important insulin-stimulated tyrosine
phophorylation of IRS-1 was occurring in cell lines expressing
the mutant receptors. Indeed, the levels of IRS-1-associated
PI3-kinase activity were at least equivalent in the Gln-1174
and Leu-1178 cell lines compared with the wild-type receptor-
expressing cell line after 100 and 1 nM insulin stimulation,
respectively.
We attempted to obtain further insights into the specific
pathways leading to downstream metabolic effects of insulin by
studying GLUT4 translocation. CHO cells do not contain the
specialized transporter GLUT4. This problem was circum-
vented by microinjecting CHO cells with vectors expressing the
wild-type or mutant receptors along with an expression vector
encoding a GFP-GLUT4 chimera. We previously demonstrated
that insulin induces the translocation of this chimera to the
plasma membrane in CHO cells stably expressing the insulin
receptor (19), an effect that is completely blocked by wortman-
nin, suggesting the central importance of PI3-kinase in this
event.3 When transiently expressed in CHO cells, only the
wild-type and not the Gln-1174 or Leu-1178 mutant insulin
receptors promoted GFP-GLUT4 translocation to the plasma
membrane, although at the same insulin concentration a sig-
nificant increase in IRS-1-associated p85a and PI3-kinase ac-
tivity was seen in these cells. This may be explained by one or
several of the following. The process may be critically depend-
ent on the amount and/or rate of PI3-kinase activation; other
events may be involved in the targeting of IRS-1 to the GLUT4-
containing vesicle; in addition to PI3-kinase, other signaling
pathways may be required to mediate insulin-stimulated
GLUT4 translocation, which is consistent with several recent
reports suggesting that activation of PI3-kinase per se may not
be sufficient to mediate GLUT4 translocation. Thus, selective
activation of PI3-kinase in 3T3-L1 adipocytes by a thiophos-
photyrosine peptide resulting in activation of PI3-kinase to
similar levels as those achieved by insulin only increased glu-
cose transport by 20% as compared with insulin-stimulated
levels (26). Although transfection studies using constitutively
active PI3-kinase in rat adipocytes resulted in cell surface
levels of GLUT4 similar to those obtained after insulin treat-
ment (27), adenovirus-mediated expression of constitutively
active PI3-kinase in 3T3-L1 adipocytes resulted in activation of
PI3-kinase to levels that exceeded the effect of insulin yet
produced only a partial stimulation of glucose transport (28).
Other ligands such as platelet-derived growth factor, which are
able to potently activate PI3-kinase, do not promote glucose
uptake in 3T3-L1 cells (29, 30). The subcellular localization of
active PI3-kinase is important for its actions on glucose trans-
port (30, 31). Thus, structural features of tyrosine-phosphoryl-
ated IRS-1 may be involved in the targeting of IRS-1 and active
PI3-kinase to specific cellular compartments. In this regard,
however, it is of interest that Isakoff et al. (32) recently re-
ported that IL4 was unable to stimulate glucose uptake despite
its ability to stimulate IRS-1 phosphorylation and enhance
IRS-1-associated PI3-kinase activity in L6 myoblasts trans-
fected with the IL4 receptor. These observations, in combina-
tion with those reported here, suggest the possibility that in-
sulin-stimulated association of PI3-kinase with IRS-1 may not
be sufficient for insulin actions on metabolic events such as
glucose transporter translocation.
To further characterize events involved in insulin’s mito-
genic actions under conditions where cells expressing the mu-
tant and wild-type receptors demonstrated comparable IRS-1
phosphorylation and PI3-kinase activation, we examined the
stimulation of MAP kinase phosphorylation and Elk-1 activa-
tion. Unlike the wild-type receptor expressing cells that stim-
ulated mitogen-activated protein kinase phosphorylation and
Elk-1 activation, both the Gln-1174 and Leu-1178 cell lines
were unable to mediate such insulin-stimulated responses to
any extent. These findings suggest that insulin-stimulated as-
sociation of PI3-kinase with IRS-1 may not be sufficient for
insulin’s actions on mitogenic events, including MAP kinase
and Elk-1 activation.
There are at least three substrates of the insulin receptor
tyrosine kinase that may act as intermediates between the
receptor and downstream events, namely IRS-1, IRS-2, and
Shc. To date, the relative roles of these and other less well-
characterized proteins in the mediation of the full repertoire of
insulin signaling has not been firmly established. Since these
mutant receptors, despite being incapable of autophosphoryla-
tion, showed the unexpected property of being able to phospho-
rylate IRS-1, we also investigated whether they were able to
phosphorylate Shc. At concentrations of insulin where clear
evidence for IRS-1 phosphorylation was seen, no phosphoryla-
tion of Shc was evident in cells expressing the mutant insulin
receptors. This dissociation between the ability of the mutant
receptors to signal to IRS-1 and Shc provided the opportunity
to use these cells as tools with which to attempt to dissect the
relative roles of IRS-1 and Shc in insulin signaling to Ras,
which is an area of some controversy (21, 24, 25). Insulin
promotes the GTP loading of Ras through the guanine nucleo-
tide exchange activity of Grb2zSos. The insulin-stimulated ty-
rosine phosphorylation of either IRS-1 or Shc, or indeed both,
and their subsequent interaction with Grb2zSos could be in-
volved in mediation of this effect. Our observation that cells
expressing mutant insulin receptors that selectively phospho-
rylate IRS-1 and not Shc show no significant insulin stimula-
tion of the GTP loading of Ras suggest that this activity may be
more closely related to Shc, rather than IRS-1, phosphoryla-
tion. In previous investigations, mutant insulin receptors in
which two of the three major tyrosine phosphorylation sites
had been replaced by phenylalanine showed a marked impair-
ment of IRS-1 phosphorylation but signaled normally to insu-
lin-stimulated Shc phosphorylation and also activated Ras (21).
Also, in Rat1 fibroblasts, the time course of insulin-stimulated
Grb2 association with Shc paralleled the time course of Shc
phosphorylation and Ras-GTP formation, with much more of
the cellular Grb2 associated with Shc than IRS-1 (25). These
data suggest that the main route from the insulin receptor to
Ras is through Shc rather than IRS-1. However, the D82 insu-
lin receptor mutant, which showed impaired phosphorylation
of Shc, was still able to mediate about 80% of the GTP loading
of Ras that was seen in wild-type cells (24). Whereas it remains
possible that the relative roles of Shc and IRS-1 in Ras activa-
tion may be cell type- specific, this does not explain the differ-
ences between our observations and Ouwens et al. (21) com-
pared with those of Yonezawa et al. (24), as all were made in
CHO cells overexpressing mutant insulin receptors.
At a concentration of insulin at which IRS-1 phosphorylation
is significantly enhanced, no phosphorylation of Shc, GTP load-
ing of Ras, phosphorylation of MAP kinase, or activation of3 S. Dobson and J. M. Tavare´, unpublished observations.
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Elk-1 is seen. In combination with our previous observations
regarding the severe impairment of insulin-stimulated mito-
genesis in these cells, these findings lend support to the notion
that Shc, rather than IRS-1, may be more centrally involved in
the growth factor-like actions of insulin. However, as it is
unlikely that all of the existing insulin receptor substrates
have, as yet, been identified and fully characterized, it is pos-
sible that molecules such as Grb10 and Grb10/IR-SV1 (33, 34)
play central roles in insulin signaling to metabolic and mito-
genic events in parallel with IRS-1 and Shc. Indeed, recent
evidence suggests that IRS-1 may not be essential for insulin-
dependent translocation of GLUT4 in 3T3-L1 cells (22).
In summary, we have studied the signaling properties of two
naturally occurring insulin receptor mutations, Gln-1174 and
Leu-1178. These mutant receptors display unusual signaling
properties that have permitted some insights into the complex-
ity of post-receptor insulin signaling. These studies have re-
vealed that 1) insulin-stimulated IRS-1 phosphorylation can
occur in the absence of detectable receptor autophosphoryla-
tion, 2) severe defects in a wide range of insulin-stimulated
metabolic and mitogenic events can occur despite substantial
phosphorylation of IRS-1 and activation of IRS-1 associated
PI3-kinase, and 3) insulin stimulation of IRS-1-associated PI3-
kinase activity per se may not be sufficient to promote GLUT4
translocation to the plasma membrane. Our data are also con-
sistent with the view that Elk-1-mediated activation of the c-fos
promoter in response to insulin requires the activation of MAP
kinase and provide support for the suggestion that the major
route involved in insulin activation of Ras is likely to be
through Shc rather than IRS-1.
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